A Human Lung Challenge Model to Evaluate the Safety and Immunogenicity of PPD and Live Bacillus Calmette-Guérin. by Davids, Malika et al.
A Human Lung Challenge Model to Evaluate the Safety and Immunogenicity of PPD 
and Live BCG
*Malika Davids1, *Anil Pooran1, Clemens Hermann2, Lynelle Mottay1, Fawziyah Thompson1, Jacob 
Cardenas3, Jinghua Gu3, Thearith Koeuth3, Richard Meldau1, Jason Limberis1, Phindile Gina1, 
Shashikant Srivastava3, Bridget Calder2, Aliasgar Esmail1, Michele Tomasicchio1, Jonathan 
Blackburn2, Tawanda Gumbo3, and Keertan Dheda1,4.
*Authors contributed equally; joint first authors 
1 Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT 
Lung Institute & South African MRC/UCT Centre for the Study of Antimicrobial Resistance, 
University of Cape Town, Cape Town, South Africa.
2Department of Integrative Biomedical Sciences, Institute of Infectious Disease & Molecular 
Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road Observatory, Cape 
Town 7925, South Africa.
3 Baylor Institute for Immunology Research, 53620, Dallas, Texas, United States.
4 Faculty of Infectious and Tropical Diseases, Department of Immunology and Infection, London 




Division of Pulmonology & UCT Lung Institute, Department of Medicine 
Old Main Building, Observatory 7439, Cape Town, South Africa
Page 1 of 62  AJRCCM Articles in Press. Published on 20-December-2019 as 10.1164/rccm.201908-1580OC 
 Copyright © 2019 by the American Thoracic Society 
Authors contributions: Study concept and design: MD, AP, JB, TG and KD; patient recruitment: 
LM, PG, and AE ; laboratory work: MD, AP, CH, FT, JC, JG, TK, RM, JL, SS, BC, and MT; analysis 
and interpretation: MD, AP, CH, FT, JC, JG, TK, RM, JL, SS, BC, MT, JB, TG, and KD; drafting of 
manuscript: MD, AP, CH, FT, JC, JG, TK, RM, JL, SS, BC, MT, JB, TG, LM, PG, AE, and KD. All 
authors gave important intellectual input. 
Short running head: A lung-orientated human infection model for TB 
Word count for manuscript body = 4055
This article has an online data supplement, which is accessible from this issue's table of content 
online at www.atsjournals.org.
Page 2 of 62 AJRCCM Articles in Press. Published on 20-December-2019 as 10.1164/rccm.201908-1580OC 
 Copyright © 2019 by the American Thoracic Society 
ABSTRACT 
Background: A human model to better understand tuberculosis immunopathogenesis and 
facilitate vaccine development is urgently needed. We evaluated the feasibility, safety, and 
immunogenicity of live Bacille-Calmette-Guerin (BCG) in a lung-orientated controlled 
human infection model. 
Methods: We recruited 106 healthy South African participants with varying degrees of 
tuberculosis susceptibility. Live BCG, sterile purified-protein-derivative (PPD), and saline 
were bronchoscopically instilled into separate lung segments (n=65). A control group 
(n=34) underwent a single bronchoscopy without challenge. The primary outcome was 
safety.  Cellular and antibody immune signatures were identified in broncho-alveolar lavage 
fluid before, and three days after challenge using flow cytometry, ELISA, RNA sequencing 
and mass spectrometry.
Findings: The frequency of adverse events was low (9.4%; n=10), similar in the challenge 
versus control groups (p=0.8), and were all mild and managed conservatively in an 
outpatient setting. The optimal PPD and BCG dose was 0.5 Tuberculin units, and 104 
colony-forming units (CFU), respectively, based on changes in BAL cellular profiles 
(p=0.02) and antibody responses (p=0.01) at incremental doses pre- versus post-challenge. 
At 104, versus 103 CFU of BCG, there was a significant increase in number differentially 
expressed genes (367 versus 3; p<0.001) and dysregulated proteins (64 versus 0; p<0.001). 
Immune responses were highly setting-specific (in-vitro versus in-vivo), compartment-
specific (BAL versus blood), and were localised to the challenged lung segments.
Conclusion: A lung-orientated mycobacterial controlled human infection model using live 
BCG and PPD is feasible and safe. These data inform the study of TB immunopathogenesis 
and strategies for evaluation and development of TB vaccine candidates. 
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Word count = 250 
At a Glance 
Scientific knowledge on the subject: Murine and non-human primate mycobacterial lung 
challenge models, using either BCG or M. tuberculosis, have provided valuable insights into 
tuberculosis (TB) immunopathogenesis at the site of disease. However, human studies using 
BCG and/or PPD lung challenge are limited. There are no published human lung challenge 
studies using PPD or live BCG in different clinical phenotypes and from a TB-endemic 
setting. The feasibility, safety, and optimal dose of BCG in this context remains to be 
clarified. 
What this study adds to the field: This ‘first-in-man study’ demonstrates that 
bronchoscopic instillation of live BCG and PPD into the lungs of healthy participants, 
representing a gradient of TB susceptibility, is safe and feasible when performed in a TB 
endemic setting. Several BCG and PPD doses were evaluated and the minimal safest 
immunogenic dose identified. These data demonstrate the safety and feasibility of a lung-
orientated mycobacterial human infection model and provide a solid foundation for the 
advancement of several lines of research including (i) the study TB immunopathogenesis, (ii) 
identification of biosignatures of TB risk, (iii) development of better models to evaluate 
vaccine efficacy, and (iv) optimising the route of vaccine delivery (respiratory tract versus 
intradermal).
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INTRODUCTION 
Tuberculosis (TB) is now the foremost infectious disease killer globally(1). Finding an 
effective vaccine represents the best hope for effective disease control but success has been 
limited. For example, MVA85A showed no added benefit over BCG in a phase IIb clinical 
trial(2) and more recently M72/AS01 exhibited a vaccine efficacy of only ~50% compared to 
a placebo(3). By contrast, measles and polio vaccines have an efficacy of more than 90%(4, 
5). The only currently licensed TB vaccine, BCG, is an attenuated strain of Mycobacterium 
bovis (M.bv) [both BCG and M.bv are part of the Mycobacterium tuberculosis complex 
(MTBC)].  Active disease due to the wild type M.bv, and sometimes even BCG (6, 7), results 
in human TB indistinguishable from that produced by the human pathogen M. tuberculosis 
(M.tb). BCG protective efficacy in adults against active TB is only ~30%(8) but is still used 
globally because it reduces the burden of disseminated  and meningeal forms of the disease 
in children(9, 10). BCG has > 99% sequence homology to M.tb at nucleotide level, 
predominantly differing by a 9.5-kb deletion of region-of-difference-1 (RD1) (11-14). 
Animal and non-human primate (NHP) studies show improved BCG efficacy when 
administered via the intrapulmonary route(15, 16). However, whether this is true in humans 
remains unclear. This is an important question because even a marginal increase in BCG 
efficacy, a low cost and globally available vaccine, will significantly reduce the worldwide 
burden of disease(17, 18). How should BCG efficacy be evaluated in humans?
Controlled human infection model [CHIM] studies in other global diseases such as malaria 
and cholera have facilitated the study of  disease pathogenesis, identification of the role of 
key virulence factors, improved vaccine efficacy, and chemotherapy(19). Given the obvious 
ethical concerns such as the requirement for complex and toxic multi-drug treatment for 6-
months, long incubation period of several months to years, and the difficulty in confirming a 
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diagnosis of active TB due to M.tb, use of BCG, which is avirulent in non-
immunosuppressed persons, could serve as a good surrogate to “simulate” M.tb infection. 
Access to such a mycobacterial-associated CHIM (mCHIM) will help address several key 
questions including better understanding TB immunopathogenesis in the human lung, the 
site of infection and disease. In addition, surrogates of protective immunity and TB risk 
remain elusive, hampering the selection of effective vaccine candidates. mCHIM in 
volunteers with different TB susceptibility profiles (ranging from sterilizing immunity to 
multiple previous episodes of active TB) could simplify and facilitate the prioritisation of 
nascent vaccine candidates (currently costs ~US$ one billion per candidate and ~15 years 
for complete development and evaluation).  Finally, a mCHIM would facilitate the 
evaluation of  intra-pulmonary versus intradermal responses to BCG. 
The quintessential first step in developing a lung-orientated mCHIM using live-BCG is to 
establish the feasibility and safety of such a model in a TB endemic country. Concerns to be 
allayed include the Koch phenomenon (a tuberculin reaction that occurs when persons 
already infected are exposed to tubercle bacilli), dose-related toxicity, and a systemic 
hypersensitivity reaction. To address the need for a mCHIM and to address other critical 
questions we evaluated the safety and feasibility of bronchoscopic installation of live BCG, 
and sterile purified-protein-derivative (PPD), in healthy South African participants 
categorized into clinical phenotypes (based on clinical, radiological and immunodiagnostic 
parameters) likely representing a gradient of TB susceptibility. Our secondary goal was to 
determine the optimal dose (or inoculum) of PPD and BCG that could be safely administered 
into the lung to produce a measurable cellular response. This foundational information could 
then be used to validate a mCHIM and design studies to address questions surrounding 
optimal route of vaccination, mycobacterial immuno-pathogenesis, biomarkers of risk and 
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protection, and as a comparative reference standard against which potential vaccine 
candidates could be evaluated. 
METHODS
Study design and participants
The study was approved by the South African Health Products Regulatory Authority 
(SAHPRA; reference 20141037), and the University of Cape Town Research Ethics 
Committee (REC/REF 659/2014) in March 2015. All participants provided written informed 
consent and were compensated for time off from work and travel. 
Between 23 June 2015 - 26 April 2019, we enrolled 106 BCG-vaccinated (at birth), HIV-
uninfected, healthy adults between 18-43 years of age in Cape Town, South Africa.  Current 
smokers and individuals with any chronic or immunocompromising illness were considered 
ineligible. Participants were categorised into four sub-groups based on clinical, radiological 
and immunodiagnostic features, which were assumed to represent a gradient of TB 
susceptibility (Figure 1). Those assumed to have a “protective” phenotype i.e. “sterilizing 
immunity” and “latent TB infection” (LTBI) groups, were asymptomatic household contacts 
of an active TB case (smear positive with cavitary disease) with no history of active disease 
and were either interferon-gamma-release-assay (IGRA; Quantiferon-TB-Gold-Plus) 
negative or positive, respectively. Those assumed to have a “susceptible” phenotype included 
participants with either a single (“previous TB”) or multiple (“recurrent TB”) episodes of 
microbiologically proven (smear, Xpert MTB/RIF or MGIT culture positive) drug-sensitive 
TB, respectively, and had completed a full course of anti-TB treatment at least six months 
prior to recruitment. All participants underwent a chest X-ray (CXR) and safety blood 
screening, including international normalized ratio, full blood count, and clinical chemistry 
(creatinine, bilirubin, ALT) at the time of enrollment. 
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Preparation of BCG and PPD
Both PPD and BCG dilutions were prepared from GMP-grade pharmaceutical stocks under 
sterile conditions. Additional details are provided in the online supplement section 1.1 and 
1.2. 
Bronchoscopic installation of saline, BCG and PPD
A baseline bronchoscopy and broncho-alveolar lavage (BAL) was performed in the right 
middle lobe (RML). Fifteen ml of BCG and PPD suspensions and of 0.9% saline were then 
instilled into the distinct lung segments. The participant returned 3 days after this initial 
procedure and a repeat bronchoscopy was performed at the site of BCG, PPD and sterile 
saline instillation. An aliquot of BAL retrieved from the BCG-challenged lung segment was 
cultured using Bactec MGIT (BD) when sufficient sample was available. Additional details 
are provided in the online supplement section 1.3.
Laboratory procedures
In vitro PPD stimulation of BAL cells: In a subset of participants, BAL cells obtained from 
the baseline bronchoscopy were cultured (~1x106) cells in 24-well plates and stimulated with 
PPD (12 µg/ml) for three days. This in vitro PPD stimulation was performed to directly 
compare the cellular phenotypes and cytokine expression to BAL cells retrieved from the 
PPD challenged segment (in vivo challenge).
Flow cytometry analysis: BAL cells and peripheral whole blood (200µl)  collected at 
baseline and three-days post lung challenge were enumerated and stained (~1x106 cells for 
BAL cells) with fluorescently conjugated antibodies for specific cell surface [CD3, CD4, 
CD8, CD25, CD69, TLR-2 (BD BioSciences, USA), CD19, CD83, CD56, HLA-DR (BD 
BioSciences, USA), CD66b] and intracellular [perforin, granulysin, IFN-, TNF-, IL-17, 
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IL-13, IL-9, and NGAL (Hycult Biotech, The Netherlands) markers], as previously 
described (20). All other antibodies were purchased from Biolegend (Biolegend, USA).
Antibody levels: Total protein concentration was determined using a BCA kit (Thermo 
Fisher Scientific) whereas antibody levels for IgG and IgA were determined by ELISA 
(Ebiosciences, USA), in BAL supernatant pre- and post-lung challenge.
Proteomic analysis: BAL supernatant was processed and underwent proteomic analysis using 
a Q Exactive mass spectrometer (Thermo Fisher Scientific). Additional details are provided 
in the online supplement sections 1.5 – 1.8. 
Transcriptomic analysis: An aliquot of pre- and post-lung challenge BAL cells were 
immediately stored in RNALater (Qiagen). RNA was then extracted and sequenced, and 
quality controls performed as described in detail in our prior publication(21). Differentially 
expressed genes [DEGs] were defined by comparing pre- and post-BCG or PPD or saline 
instillation, using a false discovery rate p<0.05, across multiple comparisons.  Additional 
details are provided in the online supplement section 1.9. 
Outcomes
The primary outcome measure of safety was assessed by comparing the frequency of 
adverse events (AEs) between challenged and non-challenged participants and the possible 
causal relationship between AEs and the instillation of BCG and PPD. Severity of the AEs 
were graded based on the DAIDS guidelines and were classified as anticipated or 
unanticipated (AEs not commonly associated with the bronchoscopy procedure).
The optimal dosage of PPD and BCG that could be safely administered in the lung to 
produce a measurable cellular response was also investigated. PPD and BCG-specific cell 
numbers, cell types, the number of differentially expressed genes and dysregulated proteins 
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(at the different BCG concentrations), cytokine responses and antibody levels (IgG and IgA) 
were determined in the cells and supernatant retrieved from BAL pre- and post-lung 
challenge. Responses were normalized to the volume of BAL fluid retrieved and compared 
to the baseline BAL. Comparisons were also made to the saline only instillation control.
Sample size calculations and statistical analysis
For immuno-phenotyping, proteomics and transcriptomic analysis at least 6 participants per 
group were necessary to detect the smallest estimated 2-fold change in specific biomarker 
expression between the groups for 70% power and 95% confidence. Statistical analyses 
were performed using GraphPad Prism version 6.0 (Graphpad software). Methods are 
provided in the online supplement. 
RESULTS 
Clinical characteristics of study participants 
We screened a total of 870 healthy adults and enrolled 106 participants who underwent a 
bronchoscopy procedure (Figure 1). The baseline demographics and clinical parameters did 
not significantly differ between the different participant groups: sterilizing immunity, latent 
TB infection (LTBI), previous TB, and recurrent TB (Table 1). 
Frequency of adverse events
In order to “abstain from doing harm”, especially from delayed hypersensitivity reactions to 
BCG and PPD (pulmonary “Koch phenomenon”), the first five study participants undergoing 
lung challenge were monitored in hospital. None of them developed a hypersensitivity 
reaction during hospitalization. After discharge they were contacted daily for the first week 
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post-challenge, then weekly until 30-days post procedure. None of them experienced any 
significant adverse events. Further recruitment was only performed after this. 
The frequency of unanticipated adverse events [AEs] in all 106 participants was 8/74 (11%) 
in challenge group versus 2/32 (6%) in controls (p=0.8) and a relative risk of 1.15 [95% 
confidence interval: 0.70-1.48], as shown in Figure 2 and online supplement table S1. The 
AEs were not severe and required only conservative clinical intervention.  The adverse 
events had a possible [7/10 participants (70%); Table 2] causal link to the bronchoscopy 
procedure, but none were found to have a causal relationship to the instillation of either BCG 
or PPD themselves (Table 2). The adverse events commonly associated with the 
bronchoscopy procedure included sore throat, shortness of breath, chest pains, cough, and 
fever. Importantly, approximately 90% of these adverse events resolved within seven days 
post procedure, and all were resolved within 14 days (Table 2). 
Bronchoscopy controls
Given the force of saline movement within a lung segment and resulting mechanical shearing 
of cells in the airway we performed a series of saline-only installation experiments to assess 
the impact of the procedure itself to produce a lung cellular response. A baseline 
bronchoscopy was performed on day zero, followed by installation with 15ml of 0.9% saline 
into three different lung segments (the same volume to be used for BCG and PPD challenge) 
of four healthy volunteers. A repeat bronchoscopy was performed three days later at the 
saline instillation sites. We found no significant differences in the number of cells per ml of 
BAL fluid obtained pre- and post-saline instillation (Figure 3A). Moreover, no significant 
changes in the expression of biomarkers associated with cytotoxicity (frequency of 
CD8+Perforin+Granulysin+; Figure 3B; p=0.7), IFN- expression by CD4+ cells (Figure 3C, 
p= 0.26), and T-cell activation (Figure 3D, p= 0.32). 
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All participants who underwent the lung challenge procedure with live BCG and sterile PPD 
also received a concurrent saline instillation in a separate lung segment. These data suggested 
that the immune response to PPD and BCG is localised to the specific lung segment into 
which it is instilled. Thus, the immunological response of the saline-only lung segment 
showed a similar immunological response (online supplement Figure S1), transcriptomic 
profile (Figure S2) and protein profile (Figure S3) to the baseline bronchoscopy. 
BCG dosage optimisation 
We performed BCG optimisation in participants with a history of prior TB using three 
different inocula (or doses) of live BCG (102, 103, and 104 CFU). We found a significant 
increase in cell numbers in the challenged lung segments only at the higher BCG dose of 104 
CFU (Figure 4A, p = 0.04). We observed the greatest immunological changes at 104 CFU, 
compared to the baseline bronchoscopy, in terms of (i) cellular phenotype [decreased 
macrophages (p=0.02), increased neutrophils (p=0.03), Figure 4B]; (ii) antibody responses 
[increased IgG levels, p= 0.01, Figure 4C and D]; (iii) the number of DEGs (367 DEGs at 
BCG 104 CFU versus 3 DEGs at BCG 103 CFU versus 3 DEGs at BCG 102 CFU; p<0.001; 
Figure 4E), (iv) higher host protein expression (64 dysregulated proteins identified at BCG 
104 CFU versus 0 at BCG 103 and 1 at 102 CFU; p<0.001; Figure 4F) and extent of protein 
dysregulation in the BAL fluid (identified by mass spectrometry, Figure S4 in the online 
supplement).
Additionally, a BCG BAL fluid sample was sent for culture in a subgroup of participants 
(n=54) and, of these participants, only 6 had a positive culture result (11%, Table S2 online 
supplement). 
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PPD dosage optimisation 
We initially tested two different PPD doses (0.2 TU and 0.5TU) intradermally in 21 healthy 
participants with a history of BCG vaccination (“primum non nocere”). We found no 
significant changes in the size of induration three days after intradermal challenge (Figure 
5A, p=0.49, n=21), and no Koch phenomenon. With that reassurance, we instilled 0.5 TU 
PPD into lung segments of these participants. There was no delayed hypersensitivity. This 
0.5 TU resulted in (i) increased antibody responses (increased IgG and IgA levels, p=0.007, 
p=0.008 respectively, Figure 5B-C); (ii) increased cell numbers in the challenged lung 
segment (figure 5D, p = 0.015), and changes in (iii) cellular phenotype [decreased 
macrophages (p=0.03), increased T-cells (p=0.01), Figure 5E]; and (iv) cytokine expression 
profiles [increased CD4+IFN- (p=0.015) and decreased CD4+CCR6+IL17+ (p=0.015), 
Figure 5F].
Immune responses in the lung versus the peripheral blood
Comparison of biomarker expression in the lung and peripheral blood at baseline indicated a 
compartment specific effect, i.e. the level of expression in lung was significantly different to 
that in the peripheral blood. For example, we found significantly higher levels of CD4+IFN-
+ (figure 6A, p<0.01), CD4+IL-9+ (figure 6A, p<0.01), CD4+IL-13+ (figure 6A, p<0.001), 
and CD4+CCR6+IL17+ (figure 6A, p<0.01) in BAL cells compared to cells in peripheral 
blood. Next, we found that in vivo stimulation with PPD yielded a different immunological 
response compared to in vitro PPD stimulation. In vivo stimulation resulted in significantly 
less expression of haemoxygenase by macrophages (figure 6B, p=0.04), myeloid-derived 
suppressor cells (figure 6B, p = 0.001), and CD8+Caspase+ (figure 6B, p=0.02).
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DISCUSSION 
This is the first study to undertake bronchoscopic instillation of live BCG and sterile PPD 
into the lungs of humans with different immune phenotypes likely representing a gradient of 
TB susceptibility.  The key findings of the study were that (i) pulmonary administration of 
live BCG, and sterile PPD, even in those with previous active TB, is safe and feasible and is 
only associated with infrequent and non-severe AEs; (ii) 104 CFU of BCG and 0.5 TU of 
PPD were the lowest possible doses that induced a detectable lung mucosal-specific immune 
responses; (iii) pulmonary immune responses to antigenic challenge were highly localised 
within a lung segment (not generalized across the entire lung) and antigen-dependent (BCG 
and PPD produced markedly different responses both in magnitude and immunotype), and 
(iv) immune responses were highly compartmentalised (lung versus blood) and model-
dependent (in vitro versus in vivo). Using a control group enabled us to demonstrate that 
most of the AEs observed were a consequence of the bronchoscopy procedure rather than 
the BCG or PPD lung challenge.
We have demonstrated the safety of lung installation of live BCG and sterile PPD at doses 
high enough to produce reliably detectable responses. We designed the study to specifically 
evaluate the risk of AEs (such as hypersensitivity reactions that Koch first described) that 
would occur in BCG-vaccinated participants with a history of prior TB. Additionally, given 
the extent of TB sensitization in this specific participant group (i.e. previous TB) we 
hypothesized that these participants should have a robust immunological recall response to 
lung challenge with PPD and/BCG. Thus, all PPD and BCG dose-related experiments were 
performed on participants with previous history of TB. Mucosal delivery of up to 4-8 x 108 
BCG CFUs as adjuvant local therapy for lung and bladder cancer lead to prolonged fevers in 
PPD skin-reactive patients; these high doses were given with the intent to stimulate a 
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therapeutic inflammatory reaction enough to slough off the cancerous cells(22, 23). In 1968, 
Rosenthal and colleagues gave nebulized BCG as an infection challenge followed by a 
tuberculin skin test(24).  However, they could not confirm that the BCG reached the alveoli 
in any reproducible manner and they did not standardise the inhaled dosage. Thus, ours is the 
first study to directly deliver BCG into the lungs of healthy participants with a spectrum of 
TB susceptibility, and to study lung-specific immunity in this context. 
The optimal dose of intrapulmonary BCG needed clarification. We were only able to 
detect a robust immunological response (transcriptomic, proteomic, and cellular), and 
significant cellular influx into the lungs at 104 CFU Rather than < 103 CFU). We also 
optimised the dose of PPD, which contains high concentrations of the complete M.tb 
antigenic repertoire (rather than the surface repertoire displayed by BCG), including RD1 
proteins(25). We detected a reliable immunological response in the lung after instilling 0.5 
TU PPD. Indeed, Silver et al found that bronchoscopic lung challenge with 0.5 TU PPD 
drove an antigen specific IFN- CD4 T-cell response in PPD responders in a low burden 
setting(26), and that the IFN- production was predominantly secreted by effector memory 
cells (27). We showed a similar pattern of lymphocytic infiltration and increase in CD4 T-
cells expressing IFN- following PPD challenge (Figure 5). Surprisingly, both in PPD and 
BCG challenged participants, the frequency of Th17 homing cells (CD4+CCR6+IL-17+), 
associated with a proinflammatory memory immune response in those with TB disease(28), 
decreased following challenge.  
The immune responses to BCG and PPD were markedly different in terms of DEGs, proteins, 
and cellular abundance. There are several potential factors which may contribute to this 
observation including (i) antigen concentration: there are no published equivalence data but 
our crude spectrophotometric-based estimation of the soluble protein fraction concentration 
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of BCG was ~10-fold lower than PPD; (ii) antigen repertoire: BCG is an attenuated strain of 
M bovis, which lacks critical virulence factors  such as EAST-6 and CFP-10, and PPD is 
comprised mainly of soluble protein with  limited polysaccharide and lipid content (25) 
whilst the BCG antigen repertoire will also include cell wall components (29);  (iii)  nature of 
antigen: PPD is ready for presentation on antigen-presenting cells allowing for faster 
initiation of adaptive immunity. Antigen-specific immune responses were also highly 
compartmentalised (dramatically different in magnitude and often higher in BAL versus 
blood). Furthermore, the segment-specific saline control (in every patient) and preliminary 
saline installation experiments (repeated bronchoscopy in three distinct lung lobes in a subset 
of individuals) demonstrated that pulmonary immune responses were highly localised within 
the specific lung challenged lung segment/s and that the bronchoscopy-specific mechano-
inflammatory effect was minimal. In addition, in vitro (harvesting of BAL cells with three-
day antigen stimulation in the laboratory) and in vivo responses (comparing the baseline to 
the three-day post challenge response) were dramatically different. These findings suggest 
that reappraisal of some of our understanding of human TB immunology would be helpful 
given that correlates of immunity are routinely measured using peripheral blood (systemic 
immunity), which do not reflect lung-compartmentalised findings (29), and the most 
commonly used assays involve in vitro stimulated cells from peripheral human blood. This 
likely means that it will be necessary to study efficacy of vaccines and identify correlates of 
protection that depend on sampling the lung, and infection/ vaccine challenges via the lung. 
There are several implications of our findings. We have taken the foundational steps in 
establishing the feasibility of a mycobacterial lung-orientated CHIM (mCHIM). Other 
investigators can now replicate this model, which will allow several important questions to be 
addressed. First, it will allow us to finally begin to address the issue of the optimal route of 
BCG vaccination in humans (intrapulmonary versus intradermal BCG vaccination efficacy).  
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This is a critical question as animal data, including non-human primates(30), suggest 
significantly higher efficacy with pulmonary BCG vaccination(15, 16) and there were higher 
frequencies of Ag85a-specfic CD4 T-cells in the lungs of participants receiving aerosolized 
MVA85A vaccine compared to intradermal administration(31). Demonstrating even a 
marginally higher efficacy with a low-cost safe vaccine will translate into significant 
reductions in disease burden. Second, mCHIM will allow us to better understand the 
immunopathogenesis of TB (we still don’t know why some people get TB and others don’t). 
Third, it will facilitate the identification of a biosignature synonymous with TB risk and 
protection, which remains a major research priority in TB for several reasons. A key 
advantage of our model is that it allows us to hierarchically rank immune responses along a 
spectrum of susceptibility in the absence of a reference standard. Fourth, mCHIM could 
provide a potential platform for the evaluation and prioritisation of new vaccine candidates 
(compared to BCG as a reference). Evaluation of new vaccine candidates is an incredibly 
long and expensive endeavour requiring large clinical trials without any guarantee of 
efficacy, even with promising preclinical results in animals.
There are several limitations of our study. (i) The biological relevance of our model is 
questionable given that BCG is not generally a pathogenic strain that causes typical TB and 
lacks critical virulence genes. However, using M.tb is neither ethical nor feasible, BCG has 
>99% sequence homology to M.tb, is an attenuated strain of M. bovis – a causative agent of 
TB clinically indistinguishable from M.tb, and BCG is part of the M.tb complex and can 
sometimes causes clinical disease compatible with active TB (7). Furthermore, it is a live 
organism delivered to the disease site and better simulates what happens in humans (the 
comparative use of PPD also allowed us, to some extent, ‘compensate’ for the effect of 
virulence factors absent from BCG).  (ii) Theoretically there could have been some cross 
priming, cross-contamination, or ‘steal effect’ between segments challenged with BCG and 
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PPD. However, the saline control indicated that was unlikely and also allowed us to 
determine the mechanical effect of the bronchoscopy procedure itself. We also took special 
care to deliver antigen in a small volume of only 15ml, followed by 60ml of air and thus 
prevented reflux from the cannulated bronchus. However, this did not exclude possible 
interaction between PPD and BCG in the draining lymph node. (iii) We did not evaluate 
long-term memory responses that would have required a longer timeframe between 
instillation and repeat bronchoscopy. However, on this first cut we chose to prioritise and 
evaluate early memory T cell responses. (iv) Our sample size in the subgroups were limited. 
However, we were well powered for safety and limited resources and funding meant that we 
were only able to perform small subgroup studies (even so, we could demonstrate significant 
inter-group differences). (v) Responses using other strains of BCG could theoretically be 
different to the Danish 1331 strain that we used(32), however, this remains the most 
commonly used strain globally. (vi) The use of general anaesthesia is considered to be very 
safe, but it does confer additional risk to study participants. Therefore, we have taken several 
precautionary steps to minimize risk including that (a) using a board-certified and accredited 
anaesthetist; (b) participants received a pre-anaesthetic consult by an independent 
anaesthetist to asses fitness for anaesthesia prior to commencing each bronchoscopy; (c) each 
participant was closely observed post-bronchoscopy until they recovered to pre-op state; (d) 
patients with specific conditions that increased associated risk were excluded (e.g. those with  
hypertension, high alcohol intake, history of smoking, drug allergies, diabetes, obesity, etc).
In conclusion, we have established that a mCHIM using live BCG and sterile PPD is feasible 
and safe in individuals from endemic countries with varying susceptibility profiles, and that 
104 CFU BCG and 0.5 TU PPD is required to elicit a detectable immunological response. 
Further studies are now required to replicate and validate this model and use it to address 
several important questions related to TB immunology and vaccinology.
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FIGURE LEGENDS
Figure 1: (A) Overview of participant groups and study procedure. (B) Trial design. (C) The 
frequency and severity of unanticipated adverse events experienced by study participants 
undergoing bronchoscopy and lung challenge with purified-protein-derivative (PPD) and live 
Bacille-Calmette-Guerin (BCG). (D) Number of participants receiving PPD and BCG doses 
for instillation into the lungs and dose optimization.
Figure 2: (A) The frequency (%) and (B) relative risk of anticipated adverse events in 
participants undergoing a single bronchoscopy (non-challenge; n=32) and those undergoing 
lung challenge with purified-protein-derivative (PPD) and Bacille-Calmette-Guerin (BCG) 
(lung challenge; n=74). (C) The frequency and severity of unanticipated adverse events 
stratified by participant subgroup (n=106).
Figure 3: The effect of bronchoscopy on lung immune responses in the saline control 
segment. We performed a baseline bronchoscopy and saline instillation into different lung 
lobes (RUL – right upper lobe; RLL: right lower lobe; LLL- left lower lobe) followed by a 
second bronchoscopy after 3 days was performed in 4 healthy individuals.  (A) Total cell 
counts were determined by microscopy. Biomarker expression was measured by flow 
cytometry for (B) perforin and granulysin expression on CD8+ T-cells, (C) CD4+IFN-γ 
expression and (D) CD4+CD69+ expression. 
Figure 4: Optimisation of the Bacille-Calmette-Guerin (BCG) concentration 
bronchoscopically instilled into the lungs using participants with a single previous 
episode of TB. Three concentrations of BCG at 102, 103 and 104 colony forming units (CFU) 
were chosen for instillation and broncho-alveolar lavage (BAL) fluid were collected from the 
challenged lung segments. Several indicators of lung-specific immunity were assessed at 
each concentration before (pre) and after BCG challenge (post). These included (A) Cell 
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numbers counted by microscopy and expressed per ml of BAL fluid. (B) The frequency of 
the different BAL cell types including macrophages (CD4+CD68+), dendritic cells 
(CD83+HLADR/DQ/DP+), natural killer cells (CD56+), T-cells (CD3+) and neutrophils 
(CD66b+NGAL+), as measured by flow cytometry. (C-D) The concentration of 
Immunoglobulin-G (IgG) and IgA antibodies, respectively, secreted in BAL fluid and 
measured by ELISA. (E) The transcriptomic profile of BAL cells as measured by RNA 
sequencing and represented as a volcano plot of individual differentially expressed genes 
(DEGs). Each concentration is compared to baseline bronchoscopy and expressed as a Log2 
fold change. Yellow dots indicate DEGs with FDR <0.05 (horizontal dashed lines) and the 
vertical dashed lines indicates Log2 fold change 1. The number of DEGs meeting these 
criteria are indicated in each volcano plot and the p-value shown in the figure compares the 
different concentrations and was calculated using the G-test (F) Proteomic analysis of BAL 
supernatants as measured by mass spectrometry and represented as volcano plots showing the 
abundance of individual proteins. Permutation-based multiple testing correction was 
performed. BCG concentrations are compared to baseline bronchoscopy (B1) and proteins 
that survived the threshold of FDR = 0.05 and S0 = 0.1 are highlighted in orange and are 
considered statistically significant. The number of dysregulated proteins (DP) meeting these 
criteria are indicated in each volcano plot and the p-value shown in the figure compares the 
different concentrations using the G-test. The number of participant samples (n) for each 
experiment are shown above the corresponding graphs. All experiments presented here were 
performed using samples from participants with a single previous episode of TB (“Previous 
TB” group). For (A-D), statistical analysis between pre- and post-challenge was performed 
using the Wilcoxon Rank sum test and a p-value<0.05 (*) was considered statistically 
significant.
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Figure 5: Optimisation of the purified-protein-derivative (PPD) concentration 
bronchoscopically instilled into the lungs of participants with a single previous episode 
of TB. (A) was initially tested by intradermal administration of the two concentrations [0.2 
tuberculin (TU) and 0.5 TU] into the skin of healthy volunteers, the size of the induration was 
measured three days later.  Subsequently, PPD was bronchoscopically instilled into the lung 
at these concentrations to determine the effect on (B-C) the concentration of 
immunoglobulin-G (IgG) and IgA antibodies, respectively, secreted in BAL fluid and 
measured by ELISA (antibody concentration measurements were performed at a PPD 
concentration of 0.5 TU only); (D) BAL cell numbers counted by microscopy and expressed 
per ml of BAL fluid; (E) The frequency of the different BAL cell types including 
macrophages (CD4+CD68+), dendritic cells (CD83+HLADR/DQ/DP+), natural killer cells 
(CD56+) and T-cells (CD3+), as measured by flow cytometry; and (F) intracellular cytokine 
expression by CD4+ T-cells including IFN-γ (Th1) and CCR6+IL-17+ (Th17 homing cells), as 
measured by flow cytometry. All experiments presented here were performed using samples 
from participants with a single previous episode of TB (“Previous TB” group). Statistical 
analysis between pre- and post-challenge was performed using the Wilcoxon Rank sum test 
and a p-value<0.05 (*) was considered statistically significant.
Figure 6: Comparison of immune responses in different biological compartments and 
using different PPD stimulation strategies as measured by flow cytometry (Th1, Th2 
and Th17) (A) Selected cytokine (Th1, Th2, Th17) responses were measured and compared 
in (A) broncho-alveolar lavage (BAL) versus peripheral blood cells retrieved prior to lung 
challenge (at baseline); (B) BAL cells retrieved from a baseline bronchoscopy, and 
stimulated with purified-protein-derivative (PPD) for 3 days in cell culture plates (in vitro) 
versus BAL cells retrieved from the PPD challenged lung segment after 3 days (in vivo). All 
experiments presented here were performed using samples from participants with a single 
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previous episode of TB (“Previous TB” group). These data are presented as median and 
interquartile range. Statistical analysis was performed using the Wilcoxon Rank sum test and 
a p-value<0.05 (*) was considered statistically significant.
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Female: n (%) 63 (59) 6 (50) 27 (82) 21 (57) 9 (38) 0.74
Age (years): 
median (#IQR) 28 (23 – 37) 26 (23-39) 31 (25-38) 27 (23-35) 28 (23-41) 0.78
Non-smokers: 
















n (%) 106 (100) 12 (100) 33 (100) 37 (100) 24 (100) n/a*
BCG vaccinated at birth: 
n (%) 106 (100) 12 (100) 33 (100) 37 (100) 24 (100) n/a*
Previous microbiologically proven 
episode of TB: n (%)
None
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Median BAL cell concentration [x105/ 
ml BAL fluid] (#IQR; n)















Saline only challenged segment 1.68 1.01 
(0.61-1.63; 10)
1.84 1.74 1.75 0.257
Page 30 of 62 AJRCCM Articles in Press. Published on 20-December-2019 as 10.1164/rccm.201908-1580OC 







































*p-values were not calculated as these parameters composed the basis of our TB susceptibility grouping. 
**p—value here was calculated based on the comparison between previous TB and recurrent TB groups. 
#interquartile range 
## QuantiFERON release assay
### tuberculin units
#### colony forming units
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Description of intervention and clinical 








Moderate Possible link to the 
bronchoscopy 
procedure
7 days Participant given an anti-viral (acylovir).
All symptoms completely resolved
T134 Sterilizing 
Immunity
Yes Passenger in a 
motor vehicle 
accident
Mild Unlikely to be 
related to the 
procedure
1 day No intervention.
T037 LTBI No Superficial 
pressure abrasion 
on lips
Moderate Definite link to the 
bronchoscopy 
procedure
7 days Participant given an anti-histamine 
(cetirizine 10mg daily).
All symptoms completely resolved.
T007 Previous 
TB
Yes Acute bronchitis Mild Possible link to the 
intervention (lung 
challenge)
7 days Participant given antibiotics, salbutamol 
and omeprazole.
All symptoms completely resolved.
T011 Previous 
TB
Yes Pyrexia Mild Possible link to the 
intervention (lung 
challenge)
1 day Participant admitted to hospital and given 
paracetamol; symptoms resolved during 
the evening. All symptoms completely 
resolved by the next day.
T026 Previous 
TB
No Epigastric pain Moderate Possible link to the 
bronchoscopy 
procedure.
4 hours Participant given antacids. 
All symptoms completely resolved.
T030 Previous 
TB
No Acute tonsillitis Moderate Unlikely to be 
related to the 
procedure.
5 days Participant given 5-day cause of oral 
antibiotics (amoxicillin + clavulanic 
acid). All symptoms completely resolved.
T048 Previous 
TB
Yes Tachycardia Mild Possible link to the 
bronchoscopy 
procedure.
1 day Patient started on amlodipine and 




Yes Acute tonsillitis Moderate Unlikely to be 
related to the 
procedure.
7 days Participant given oral antibiotics 
(amoxycillin).
All symptoms completely resolved.
T074 Recurrent 
TB







Patient blood pressure was well 
controlled. Patient referred primary 
health facility for further continued 
monitoring.
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Figure 1: (A) Overview of participant groups and study procedure. (B) Trial design. (C) The frequency and 
severity of unanticipated adverse events experienced by study participants undergoing bronchoscopy and 
lung challenge with purified-protein-derivative (PPD) and live Bacille-Calmette-Guerin (BCG). (D) Number of 
participants receiving PPD and BCG doses for instillation into the lungs and dose optimization. 
1053x595mm (96 x 96 DPI) 
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Figure 2: (A) The frequency (%) and (B) relative risk of anticipated adverse events in participants 
undergoing a single bronchoscopy (non-challenge; n=32) and those undergoing lung challenge with purified-
protein-derivative (PPD) and Bacille-Calmette-Guerin (BCG) (lung challenge; n=74). (C) The frequency and 
severity of unanticipated adverse events stratified by participant subgroup (n=106). 
562x711mm (96 x 96 DPI) 
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Figure 3: The effect of bronchoscopy on lung immune responses in the saline control segment. We 
performed a baseline bronchoscopy and saline instillation into different lung lobes (RUL – right upper lobe; 
RLL: right lower lobe; LLL- left lower lobe) followed by a second bronchoscopy after 3 days was performed in 
4 healthy individuals.  (A) Total cell counts were determined by microscopy. Biomarker expression was 
measured by flow cytometry for (B) perforin and granulysin expression on CD8+ T-cells, (C) CD4+IFN-γ 
expression and (D) CD4+CD69+ expression. 
916x590mm (96 x 96 DPI) 
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Figure 4: Optimisation of the Bacille-Calmette-Guerin (BCG) concentration bronchoscopically instilled into 
the lungs using participants with a single previous episode of TB. Three concentrations of BCG at 102, 103 
and 104 colony forming units (CFU) were chosen for instillation and broncho-alveolar lavage (BAL) fluid were 
collected from the challenged lung segments. Several indicators of lung-specific immunity were assessed at 
each concentration before (pre) and after BCG challenge (post). These included (A) Cell numbers counted by 
microscopy and expressed per ml of BAL fluid. (B) The frequency of the different BAL cell types including 
macrophages (CD4+CD68+), dendritic cells (CD83+HLADR/DQ/DP+), natural killer cells (CD56+), T-cells 
(CD3+) and neutrophils (CD66b+NGAL+), as measured by flow cytometry. (C-D) The concentration of 
Immunoglobulin-G (IgG) and IgA antibodies, respectively, secreted in BAL fluid and measured by ELISA. (E) 
The transcriptomic profile of BAL cells as measured by RNA sequencing and represented as a volcano plot of 
individual differentially expressed genes (DEGs). Each concentration is compared to baseline bronchoscopy 
and expressed as a Log2 fold change. Yellow dots indicate DEGs with FDR <0.05 (horizontal dashed lines) 
and the vertical dashed lines indicates Log2 fold change 1. The number of DEGs meeting these criteria are 
indicated in each volcano plot and the p-value shown in the figure compares the different concentrations and 
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was calculated using the G-test (F) Proteomic analysis of BAL supernatants as measured by mass 
spectrometry and represented as volcano plots showing the abundance of individual proteins. Permutation-
based multiple testing correction was performed. BCG concentrations are compared to baseline 
bronchoscopy (B1) and proteins that survived the threshold of FDR = 0.05 and S0 = 0.1 are highlighted in 
orange and are considered statistically significant. The number of dysregulated proteins (DP) meeting these 
criteria are indicated in each volcano plot and the p-value shown in the figure compares the different 
concentrations using the G-test. The number of participant samples (n) for each experiment are shown 
above the corresponding graphs. All experiments presented here were performed using samples from 
participants with a single previous episode of TB (“Previous TB” group). For (A-D), statistical analysis 
between pre- and post-challenge was performed using the Wilcoxon Rank sum test and a p-value<0.05 (*) 
was considered statistically significant. 
231x338mm (300 x 300 DPI) 
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Figure 5: Optimisation of the purified-protein-derivative (PPD) concentration bronchoscopically instilled into 
the lungs of participants with a single previous episode of TB. (A) was initially tested by intradermal 
administration of the two concentrations [0.2 tuberculin (TU) and 0.5 TU] into the skin of healthy 
volunteers, the size of the induration was measured three days later.  Subsequently, PPD was 
bronchoscopically instilled into the lung at these concentrations to determine the effect on (B-C) the 
concentration of immunoglobulin-G (IgG) and IgA antibodies, respectively, secreted in BAL fluid and 
measured by ELISA (antibody concentration measurements were performed at a PPD concentration of 0.5 
TU only); (D) BAL cell numbers counted by microscopy and expressed per ml of BAL fluid; (E) The frequency 
of the different BAL cell types including macrophages (CD4+CD68+), dendritic cells 
(CD83+HLADR/DQ/DP+), natural killer cells (CD56+) and T-cells (CD3+), as measured by flow cytometry; 
and (F) intracellular cytokine expression by CD4+ T-cells including IFN-γ (Th1) and CCR6+IL-17+ (Th17 
homing cells), as measured by flow cytometry. All experiments presented here were performed using 
samples from participants with a single previous episode of TB (“Previous TB” group). Statistical analysis 
between pre- and post-challenge was performed using the Wilcoxon Rank sum test and a p-value<0.05 (*) 
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was considered statistically significant. 
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Figure 6: Comparison of immune responses in different biological compartments and using different PPD 
stimulation strategies as measured by flow cytometry (Th1, Th2 and Th17) (A) Selected cytokine (Th1, Th2, 
Th17) responses were measured and compared in (A) broncho-alveolar lavage (BAL) versus peripheral blood 
cells retrieved prior to lung challenge (at baseline); (B) BAL cells retrieved from a baseline bronchoscopy, 
and stimulated with purified-protein-derivative (PPD) for 3 days in cell culture plates (in vitro) versus BAL 
cells retrieved from the PPD challenged lung segment after 3 days (in vivo). All experiments presented here 
were performed using samples from participants with a single previous episode of TB (“Previous TB” group). 
These data are presented as median and interquartile range. Statistical analysis was performed using the 
Wilcoxon Rank sum test and a p-value<0.05 (*) was considered statistically significant. 
175x260mm (300 x 300 DPI) 
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1. METHODS
1.1 Preparation of BCG
Bacille-Calmette-Guerin (BCG) culture SSI (Statum Serum Institute, Copenhagen, 
Denmark) was sourced for lung challenge experiments. Each tube comprised of a semi-dry 
mass of ~2.5X108 colony-forming-units (CFU) of Mycobacterium Bovis BCG (Danish 
strain 1331). The contents were reconstituted in 1ml of sterile 0.9% saline and serial 
dilutions were subsequently made to obtain concentrations of 1x103, 1x104 and 1x105 
CFU/ml for dose optimization studies. 100l of each dilution was mixed into 15ml of sterile 
saline and instilled into the lung via bronchoscopy (giving a final CFU count of 1x102, 
1x103 and 1x104, respectively). All dilutions were plated on 7H9 agar plates to confirm the 
CFU count at each dilution and bacterial viability. 
1.2 Preparation of purified protein derivative (PPD)
Tuberculin PPD RT/23 (Statum Serum Institute, Copenhagen, Denmark) was sourced for 
skin testing and lung challenge experiments. Skin challenge was initially performed for PPD 
dose finding investigations. 100ul of Tuberculin PPD RT/23 at 5 Tuberculin units (TU)/ml 
and 2 TU/ml (equating to a final concentration of 0.5 and 0.2 TU, respectively) were 
simultaneously administered intradermally into the left and right forearms, respectively, of 
healthy individuals. The size of the induration was measured after 3 days. For lung 
challenge experiments, 100µl of 5TU and 2TU PPD (equating to a final concentration of 0.5 
and 0.2 TU, respectively) was mixed in 15ml of sterile 0.9% saline and subsequently 
instilled into the lung via bronchoscopy (see below).      
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Both PPD and BCG dilutions were prepared from GMP-grade pharmaceutical stocks in a 
Class II bio-safety cabinet under sterile conditions. As such, no testing for 
lipopolysaccharides or other contaminants was performed.
1.3 Bronchoscopy procedure
All bronchoscopies were performed by the study pulmonologist at the E-16 Respiratory 
Clinic at Groote Schuur Hospital, Cape Town. Study participants remained starved for at 
least 12 hours before and at least 2 hours after the procedure to minimize the risk of 
aspiration. Also prior to the procedure, a blood sample was collected and participants 
underwent a physical examination and were questioned regarding symptoms of cough, 
sputum production, dyspnea or chest pain. At the start of the bronchoscopy, participants 
were placed under general anaesthesia using a combination of fentanyl, midazolam and 
propofol (administered by a qualified anaesthetist). A laryngeal mask (LMA) was used to 
protect the airway.  2% lidocaine was topically applied to the nasal passage and throat 
followed by intubation and insertion of a fibreoptic flexible bronchoscope into the airways.  
1.4 Post-bronchoscopy procedure recovery and follow up
Upon completion of the procedure (baseline and repeat bronchoscopies), participants were 
allowed to recover under close observation by the research nurse and anesthetist. Each 
participant was intensively followed up post-procedure (either telephonically or by home 
visit) by the research nurse daily for the first week, twice a week for the next month and 
weekly for the final two months (a total of three months). The frequency and description of 
any adverse events were recorded by the research nurse. Given the novelty of PPD and BCG 
lung challenge, especially in individuals from endemic countries with high M. tb exposure, 
the first five recruited participants were hospitalized post-procedure for intensive clinical 
monitoring. 
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1.5 Bronchoalveolar lavage processing for proteomic analysis 
Cell-free bronchoalveolar lavage fluid (BALF) was stored in 15 ml aliquots at -80°C until 
further use. Each aliquot was thawed, debris removed by centrifugation at 3000 x g for 10 
minutes and the resulting supernatant filtered through a 0.20 µm filter. The BALF was further 
concentrated to a volume of 1-2 ml using an Amicon Ultra-4ml Centrifugal Filter Unit 
(Sigma) with a 3 kDa molecular weight cut-off. Filters were prewashed PBS pH 7.4 prior to 
use. Protein concentration was estimated using a BCA protein quantitation kit (Thermo).
1.6 Immuno-depletion and sample preparation for proteomic analysis
One hundred µg of protein per patient was diluted in Buffer A (Agilent) and immunodepleted 
using a MARS HU-6 column (Agilent) according to manufacturers’ instructions. The column 
was washed twice with Buffer A and the resulting fractions combined. The bound high-
abundance proteins were eluted using Buffer B (Agilent). Unbound fractions were buffer 
exchanged into denaturation buffer (6 M urea, 2 M thiourea, 10 mM Tris pH 8.0) and 
concentrated to a volume of 100-200 µl using an Amicon Ultra-0.5ml Centrifugal Filter Unit 
(Sigma) with a 3 kDa molecular weight cut-off. Proteins were reduced with dithiothreitol at a 
final concentration of 1 mM for 1 hour at room temperature. Free cysteine residues were 
alkylated by incubation in 5.5 mM iodoacetamide for 1 hour at room temperature in the dark. 
Samples were diluted with 4 volumes of 20 mM ammonium bicarbonate buffer pH 8.0 with 
20 mM CaCl2 and proteins digested with 2 ug of sequence-grade trypsin (NEB) at room 
temperature for 18 hrs. Digestion was stopped by addition of 0.1% formic acid (Sigma). 
Tryptic peptides were desalted using homemade STAGE tips containing Empore Octadecyl 
C18 solid-phase extraction disks (Supelco). C18 disks were activated with three washes with 
solvent B (80% acetonitrile, 0.1% formic acid) and equilibrated with three washes with 
solvent A (2% acetonitrile, 0.1% formic acid). Approximately 10 μg of tryptic peptides were 
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loaded onto the C18 disc, centrifuged at 4000 × g for 1 minute and washed three times with 
solvent A. Peptides were then eluted three times with solvent C (60% acetonitrile, 0.1% 
formic acid) into glass capillary tubes. Eluted peptides were dried in a vacuum and 
resuspended with solvent A (2% acetonitrile, 0.1% formic acid) at a concentration of about 
200 ng/μl prior to measurement. A pool of all samples was created for quality assurance 
during measurements. 
1.7 LC-MS/MS analysis
Separation of peptides by liquid chromatography was performed using a homemade 100 μm 
ID × 20mm precolumn packed with C18 Luna beads (5 μm diameter, 100 Å pore size; 
Phenomenex 04A-5452) connected to a 75 μm × 200mm analytical column packed with 
Aeris peptide C18 beads (3.6 um diameter; Phenomenex 00B-4507-AN) connected to an 
Ultimate 3500 RS nano UPLC system (Dionex). Desalted peptides were loaded onto the 
column with a starting mobile phase of 2% ACN, 0.1% formic acid and separated at a 
constant flow rate at 400 nL/minute by the following gradient: 10 minute at 2% ACN, 
increase to 6% ACN for 2 minute, to 30% ACN over 120 minute, to 80% ACN over 5 
minute, followed by a column wash of 80% for 13 minute. Mass spectra were collected on a 
Q Exactive mass spectrometer (Thermo) in a data-dependent manner with automatic 
switching between MS and MS/MS scans using a top-10 method. Peptides were ionised by 
electrospray ionisation and MS spectra were acquired at a resolution of 70,000 with a target 
value of 3 × 106 ions or a maximum integration time of 250 ms. The scan range was restricted 
between 300 and 1750 m/z. Peptide fragmentation was performed by higher-energy collision 
dissociation (HCD) with the energy set at 25 NCE. Intensity threshold for ions selection was 
fixed at 1.7 × 104 with charge exclusion of z=1 and z > 5. The MS/MS spectra were acquired 
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at a resolution of 17,500, with a target value of 2 × 105 ions or a maximum integration time of 
120 ms and the isolation window was set at 4.0 m/z.
1.8 Proteomic data analysis
RAW data files were processed with MaxQuant version 1.5.4.1 for protein and peptide 
identification using the Andromeda search engine and the Uniprot proteomes for Homo 
sapiens (Proteome ID: UP000005640, 71785 proteins, 07/02/2018), M. bovis BCG Pasteur 
(Proteome ID: UP000001472, 3891 proteins, 03/09/2018) and M. tuberculosis H37Rv 
(Proteome ID: UP000001584, 3993 proteins, 03/01/2018). Default parameter settings were 
used for the MS/MS database search, with carbamidomethylation of cysteine residues and 
acetylation of the protein N-terminus selected as fixed modifications. 
Trypsin/P was selected as protease, label-free quantitation (LFQ) and the “match between 
runs” feature were enabled. Reverse hits and common contaminants were removed from the 
data sets and only protein identifications with a q-value < 0.01 were considered for the further 
analysis. Data analysis was performed in Perseus version 1.6.2.3. For each comparison, LFQ 
values were log2(x) transformed. Dysregulated proteins were identified by volcano plot 
analysis using permutation-based multiple testing correction. Values for determining 
significantly dysregulated proteins were kept at the default settings of FDR = 0.05 and 
background variability S0 = 0.1.
1.9 Transcriptomic analysis 
1.9.1 Bioinformatics analysis: Quality assessment on raw sequencing reads was performed 
using FastQC1. The adapters were trimmed and low-quality reads (< 20) were filtered using 
cutadapt2. Reads were aligned to the human reference genome (GRCh38)3 using hisat24. 
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Aligned SAM files were converted to BAM format using samtools5 and feature Counts6 was 
used to quantify total number of counts for each gene.
1.9.2 RNA-Seq analysis: Differential gene expression (DGE) analysis using a within and 
between subject design was performed with DESeq2 7. Three days after an initial baseline 
saline challenge, subjects were challenged with BCG and split into three groups based on 
BCG concentration used (102, 103, or 104 CFU). All participants had a sample in only one 
concentration group, except for subject T011 (102 and 104 CFU). Comparisons were made to 
baseline within each group. 
1.9.3 Modular analysis: Modular analysis was performed using a pre-existing framework 
of 260 transcriptional modules 8, and we present a subset that have been functionally 
annotated. For each comparison and within each module, the percentage of transcripts 
significantly up- or down-regulated based on p-value and fold-change (FC) was calculated (
), and the module score was defined as the difference in percent up or 𝑝 ≤ 0.05, |FC| ≥ 1.5
down. 
1.9.4 RNA-Seq data visualization: Counts were normalized using the median-of-ratios 
method 9 and log2 transformed for principal component analysis (PCA), hierarchical 
clustering, and data visualization. The transcripts of all heatmaps were hierarchically 
clustered using Euclidean distance and complete linkage function. The heatmaps and PCA 
plots were created using R v3.5.2 packages NMF 10 and ggplot2 11, respectively.
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Table S1: Stratification of anticipated adverse events experienced by participants in the different susceptibility groups at different 

























Baseline Day 0 6 (8) 21 (29) - 2 (3) - 1 (1) 11 (15)
Post lung challenge 1-day 1 (1) 26 (36) - 4 (5) - 2 (3) 7 (10)
All: 
n = 73
Post lung challenge 30 days - 2 (3) - - - - -
Baseline Day 0 1 (9) - - - - - -
Post lung challenge 1-day - 2 (18) - - - - -
Sterilizing Immunity
n = 11
Post lung challenge 30 days - - - - - - -
LTBI Baseline Day 0 2 (7) 7 (24) - 2 (7) - - 2 (7)
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Post lung challenge 1-day - 7 (24) - 1 (3) - - 2 (7)
n = 29 Post lung challenge 30 days - - - - - - -
Baseline Day 0 2 (8) 11 (44) - - - 1 (4) 8 (32)
Post lung challenge 1-day - 13 (52) - 3 (12) - 2 (8) 4 (16)
Previous TB
n = 25
Post lung challenge 30 days - 2 (8) - - - - -
Baseline Day 0 1 (13) 3 (38) - - - - 1 (13)
Post lung challenge 1-day 1 (13) 4 (50) - - - - 1 (13)
Recurrent TB
n = 8
Post lung challenge 30 days - - - - - - -
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Table S2:  BCG culture results performed on BAL fluid retrieved from the BCG 
challenged lung segment after 3 days post instillation in the different TB susceptibility 
groups. A 10ml aliquot of BAL fluid was cultured using the Mycobacterial-Growth-In-Tube 
liquid culture system.














All 54 1 (102 CFU)
2 (103 CFU)
52 (104 CFU)
49 (91) 5 (9) 22
Sterilizing 
immunity 
7 0 (102 CFU)
0 (103 CFU)
7 (104 CFU)
6 (86) 1 (14) 23
Latent TB infection 25 0 (102 CFU)
0 (103 CFU)
25 (104 CFU)
23 (92) 2 (8) 25
Previous TB 13 0 (102 CFU)
2 (103 CFU)
13 (100) 0 (0) n/a
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11 (104 CFU)
Recurrent TB 9 0 (102 CFU)
0 (103 CFU)
9 (104 CFU)
7 (78) 2 (22) 19
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Figure S1: Cytokine expression by CD4 T cells isolated from broncho-alveolar lavage 
fluid (BALF) recovered from the saline only control segments in participants challenged 
with BCG and PPD. (A) level of IFN-gamma expression, (B) IL-13 expression, (C) IL-17 
expression, and (D) IL-9 expression. Statistical significance was determined using the 
Wilcoxon matched-pairs signed rank. * indicates p<0.05. (No significance was observed).
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Figure S2. RNA expression in broncho-alveolar lavage (BAL) cells recovered from the saline only control 
segments in participants challenged with BCG alone or together with PPD in different lung segments. 
Transcriptomic analysis of BAL cells using RNAseq represented as volcano plots showing the differentially 
expressed genes (DEGs) in the saline only segment compared to pre-challenge baseline (B1) in previous TB 
participants and expressed as a Log2 fold change. Data is shown for (A) all participants (n=17) (B) participants 
who only received BCG lung challenge (n=6) and (C) participants who received both BCG and PPD (n=11). 
Yellow dots indicate DEGs with Log2 fold change≥1 (horizontal dashed lines) and an FDR of <0.05 after 
multiple comparison corrections (vertical dashed lines). The number of DEGs meeting these criteria are 
indicated in each volcano plot.
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Figure S3: Protein expression in broncho-alveolar lavage (BAL) supernatant recovered from the saline 
only control segments in participants challenged with BCG alone or together with PPD in different lung 
segments. (A) Total protein (in mg) measured using BCA assay in BAL supernatants from the saline control 
segment and compared to the pre-challenge bronchoscopy (B1). (B-D) Proteomic analysis of BAL supernatants 
using mass spectrometry and represented as volcano plots showing the abundance of individual proteins in the 
saline only segment compared to pre-challenge baseline (B1) in previous TB participants. Data is shown for (B) 
all participants (n=12) (C) participants who only received BCG lung challenge (n=6) and (D) participants who 
received both BCG and PPD (n=6). Permutation-based multiple testing correction was performed. Proteins that 
survived the threshold of FDR = 0.05 and S0 = 0.1 are highlighted in orange and are considered statistically 
significant (No significance was observed).
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Figure S4: Total protein amount in broncho-alveolar lavage (BAL) supernatant obtained from the BCG 
challenged lung segment in participants challenged with different concentrations of BCG. Total protein was 
measured using the BCA assay.  Statistical significance was determined using Kruskal-Wallis test followed by 
Dunn’s Multiple Comparisons test. * indicates p<0.05
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Figure S5: Transcriptomic changes from baseline induced by different concentrations of BCG challenge. (A) Baseline subtracted heatmap of 281 differentially 
expressed genes that survived FDR < 0.05 and |FC| > 2 in BCG 10e4 vs baseline comparison. (B) Modular map showing the difference in percent of genes within a module 
significantly up- vs down-regulated for each concentration. Significance was determined by the threshold p < 0.05 and |FC|> 1.5.  
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Table S3: Transcriptomic analysis showing the top differentially expressed genes (DEGs) post BCG (104, 103, 
and 102 CFU). 
104 CFU BCG: Top 10 differentially expressed genes
Gene Symbol Base mean log2 fold change p-value adjusted p-value
ENSG00000108700 CCL8 50.27 4.15 2.51E-07 0.000223145
ENSG00000212579 RF00561 21.59 3.83 2.13E-05 0.004483548
ENSG00000229961 AL357143.1 8.52 3.73 7.40E-06 0.002158399
ENSG00000104921 FCER2 10.29 3.49 3.71E-06 0.001394647
ENSG00000164509 IL31RA 5.51 3.38 8.55E-05 0.011826461
ENSG00000108688 CCL7 3.00 3.37 0.000650516 0.043039121
ENSG00000229754 CXCR2P1 15.24 3.30 1.98E-07 0.00020609
ENSG00000138061 CYP1B1 28.84 3.04 1.24E-06 0.000643862
ENSG00000253838 AC007991.2 16.10 2.99 4.54E-05 0.007493106
ENSG00000239961 LILRA4 7.41 2.87 0.000405156 0.031850357
103 CFU BCG: Differentially expressed genes
Gene Symbol Base mean log2 fold change p-value adjusted p-value
ENSG00000121807 CCR2 264.66 1.70 5.48E-06 0.038894016
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102 CFU BCG: Differentially expressed genes
Gene Symbol Base mean log2 fold change p-value adjusted p-value
ENSG00000185303 SFTPA2 34.26 2.27 1,37E-09 2,93E-05
ENSG00000168878 SFTPB 36.04 2.3 5,59E-08 0,000595155
ENSG00000010327 STAB1 109.21 1.86 1,28E-07 0,000905828
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Table S4: Mass spectrometry analysis showing the top secreted proteins post BCG (104, 103, and 102 CFU) as compared to baseline bronchoscopy.
104 CFU BCG: Top secreted proteins
Majority protein IDs Protein names Gene names Significant
Difference 
(10e4-B1)





Salivary acidic proline-rich phosphoprotein 1/2; Salivary 
acidic proline-rich phosphoprotein 1/2; Salivary acidic 
proline-rich phosphoprotein 3/4; Peptide P-C
PRH1 + -4,28 1,63
P61626; F8VV32; A0A0B4J259 Lysozyme C;Lysozyme LYZ + -3,65 3,09
A0A087WY73; Q16378 Proline-rich protein 4 PRR4 + -3,46 1,83
P80723 Brain acid soluble protein 1 BASP1 + -3,13 2,11
P62328 Thymosin beta-4; Hematopoietic system regulatory peptide TMSB4X + -2,94 1,64
Q13740;F5GXJ9 CD166 antigen ALCAM + -2,85 1,88
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P04745; P19961; P04746





P11684 Uteroglobin SCGB1A1 + -2,59 1,69
Q96S96 Phosphatidylethanolamine-binding protein 4 PEBP4 + -2,50 2,15
102 CFU BCG: Top secreted proteins







Q99878; Q96KK5; Q9BTM1; 
P20671; P0C0S8; H0YFX9
Histone H2A type 2-C; Histone H2A type 2-A; Histone 
H2A type 1-J; Histone H2A type 1-H; Histone H2A.J; 







HIST1H2AG + 2,72 5,30
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